AngioDynamics, Inc. (ANGO) - 10-K Summary
Business Context and Reporting Period
This summary covers the Annual Report on Form 10-K for AngioDynamics, Inc. for the fiscal year ended May 31, 2026. AngioDynamics is a medical technology company focused on cardiovascular disease and cancer treatment, operating through two segments: Med Tech (high-growth technologies like Auryon, NanoKnife, and thrombus management) and Med Device (vascular access, ports, and oncology products). The company is headquartered in Latham, New York, and trades on the NASDAQ Global Select Market.
Key Financial Metrics
| Metric | Fiscal 2026 | Fiscal 2025 | Change |
|---|---|---|---|
| Net Sales | $320.2 million | $292.5 million | +9.5% |
| Gross Margin | 54.6% | 53.9% | +70 bps |
| Net Loss | $(36.7) million | $(34.0) million | Widened by $2.7M |
| Loss Per Share (Diluted) | $(0.88) | $(0.83) | Widened by $0.05 |
| Cash Flow from Operations | $3.1 million | $(10.1) million | Improved by $13.2M |
| Cash and Equivalents | $53.9 million | $55.9 million | Decreased by $2.0M |
| Debt | $0 | $0 | No change |
Segment Performance: Med Tech revenue grew 18.4% to $150.0 million, driven by Auryon, NanoKnife, and thrombus management products. Med Device revenue grew 2.6% to $170.2 million, with growth in Core and Venous products offset by declines in Ports and other Oncology products.
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by the Med Tech segment, specifically a $10.0 million increase in Auryon sales and an $8.6 million increase in NanoKnife sales.
- Operating Expenses: Selling and marketing expenses increased by $10.3 million, primarily due to higher compensation and benefits. Research and development expenses rose $3.2 million due to clinical trial timing.
- Restructuring and One-Time Items: "Acquisition, restructuring and other items, net" totaled $17.6 million, including $13.1 million in plant closure expenses related to the manufacturing footprint optimization and $1.6 million in CEO transition costs.
- Divestitures: The company completed the manufacturing transfer milestone for previously divested businesses (PICC/Midline to Spectrum Vascular), recognizing $5.0 million in revenue.
- Legal Settlements: The company made a $2.5 million minimum annual payment to Becton, Dickinson and Company (BD) under a patent settlement agreement.
Guidance, Outlook, and Risks
Strategic Initiatives: Management is executing a restructuring plan to shift manufacturing to third-party partners, expected to be completed in Q1 FY2027, with projected annual cost savings of $15.0 million starting in FY2027. The company is focusing on clinical trials for Auryon (AMBITION BTK) and NanoKnife (RELIEF BPH, PRESERVE study).
Liquidity: The company maintains a $25.0 million secured revolving credit facility with JPMorgan Chase, with no outstanding balance as of May 31, 2026. Management believes current cash and operating cash flow are sufficient for the next 12 months.
Key Risks and Contingencies:
- CEO Transition: CEO James C. Clemmer has announced his intention to retire by November 30, 2026, or upon appointment of a successor.
- Product Liability: The company is defending approximately 412 consolidated product liability claims related to its port products in the U.S. District Court for the Southern District of California.
- Regulatory: Ongoing compliance with FDA Quality System Regulations and European MDR requirements remains critical. The company faces risks related to reimbursement rates and third-party payer policies.
- Supply Chain: Reliance on single-source suppliers and the transition to outsourced manufacturing present operational risks.
Investor Verification Checklist
- Restructuring Execution: Verify the timeline and cost savings realization of the manufacturing transition to third-party partners scheduled for completion in FY2027.
- Product Liability Exposure: Monitor the status of the 412 consolidated port product liability claims and potential impact on insurance coverage or reserves.
- CEO Succession: Track the progress of the CEO search and the stability of operations during the transition period.
- Clinical Trial Outcomes: Review results from the AMBITION BTK (Auryon) and RELIEF BPH (NanoKnife) trials, which are critical for future revenue growth.
- Inventory Levels: Assess the adequacy of inventory reserves given the company's focus on reducing excess inventory, which contributed to positive operating cash flow in FY2026.